인공 고관절 및 인공 슬관절 시장 : 관절 유형, 고정 유형, 재료 유형, 수술 유형, 최종사용자별 - 세계 예측(2025-2030년)

The Artificial Hip & Knee Joints Market was valued at USD 10.94 billion in 2024 and is projected to grow to USD 11.39 billion in 2025, with a CAGR of 4.19%, reaching USD 14.01 billion by 2030.

Exploring the evolving artificial hip and knee joint market landscape shaped by cutting-edge technological breakthroughs patient outcomes and emerging strategic opportunities

In the past decade, the artificial hip and knee joint arena has transformed from mechanically basic prostheses to sophisticated biomechanically engineered solutions that prioritize patient mobility and comfort. This evolution has been driven by relentless innovation in materials science, surgical instrumentation, and rehabilitation protocols, which collectively aim to extend the functional lifespan of implants while minimizing recovery time.

Emerging additive manufacturing techniques have enabled the creation of complex porous structures that enhance osseointegration, while improvements in polymer and ceramic compounds have reduced wear rates and adverse tissue reactions. Concurrently, the integration of digital planning tools and intraoperative navigation has increased surgical precision, thereby elevating overall patient outcomes. Consequently, decision-makers are now tasked with evaluating a rapidly expanding portfolio of implant designs underpinned by distinct clinical value propositions.

This executive summary distills these multifaceted developments into actionable insights, offering a concise yet comprehensive overview of the current market landscape. By articulating key technological advances, regulatory considerations, and strategic imperatives, this section lays the groundwork for understanding the critical drivers propelling the sector forward and the opportunities that lie ahead for stakeholders across the ecosystem.

Unveiling the disruptive technological and clinical shifts including robotic-assisted surgery additive manufacturing biomaterials innovations and personalized patient pathways altering market dynamics

Robotic-assisted surgical platforms have redefined precision in joint replacement procedures, enabling surgeons to execute bone resections with sub-millimeter accuracy. This heightened precision not only improves prosthesis alignment but also contributes to reduced intraoperative variability and postoperative complications.

Innovation in patient-specific instrumentation has further personalized operative workflows. Customized cutting guides and implant components derived from preoperative imaging data allow for tailored anatomical congruence and load distribution. As a result, surgeons can achieve optimized biomechanical performance, thereby enhancing implant longevity.

Advances in biomaterial formulations have introduced new generations of coatings that promote rapid bone cell adhesion while mitigating inflammatory responses. Meanwhile, digital health applications are revolutionizing postoperative care through remote monitoring of rehabilitation milestones, pain metrics, and activity levels. Together, these converging trends underscore a shift from one-size-fits-all solutions to integrated care models that align with precision medicine principles. As the landscape continues to evolve, stakeholders must adapt to these paradigm shifts and leverage interdisciplinary collaboration to unlock enhanced patient outcomes and sustainable growth.

Assessing the cumulative impact of new United States tariff measures introduced in 2025 on supply chain costs component sourcing regulatory compliance and pricing strategies for implants

In 2025, a series of tariff revisions implemented by the United States government has introduced new challenges for manufacturers and suppliers of artificial hip and knee joints. These measures have primarily targeted imported implant components and raw material inputs, including specialized alloys and advanced polymer composites. The upward adjustments in import duties have incrementally increased manufacturing costs, prompting original equipment manufacturers to revisit their sourcing strategies.

Manufacturers have responded by accelerating diversification of their supply chains, establishing localized production sites, or securing preferential trade agreements to mitigate cost escalations. In tandem, some implant developers have initiated strategic partnerships with domestic machining and coating specialists to ensure continuity of high-precision component availability while stabilizing overhead expenses.

Furthermore, the adjusted tariff landscape has influenced pricing strategies across the distribution channel. Healthcare providers are negotiating new contract terms to balance implant acquisition costs against reimbursement frameworks, which in many cases have not kept pace with tariff-driven inflation. Simultaneously, ongoing dialogues with regulatory authorities seek to harmonize tariff relief provisions for medical devices, highlighting the critical role of policy advocacy in preserving access to advanced joint replacement solutions. Overall, the cumulative impact of the 2025 tariff adjustments underscores the imperative for agile operational models, robust risk management, and proactive engagement with both trade partners and regulatory bodies.

In the long term, these tariff measures may incentivize investment in domestic R&D and manufacturing infrastructure, potentially accelerating innovation cycles and reducing dependency on cross-border supply routes. However, the transitional period demands vigilant cost control and collaboration across the value chain to safeguard patient access to state-of-the-art implants without compromising clinical excellence.

Revealing critical segmentation insights across joint type fixation mechanisms material selections surgical procedures and end user environments driving differentiated market strategies

Deep segmentation analysis reveals nuanced market behaviors when viewed through multiple lenses. By considering joint type, clinicians and manufacturers differentiate between hip and knee applications, each presenting distinct biomechanical challenges, patient demographics, and rehabilitation protocols. The fixation mechanism dimension further delineates fixed-bearing constructs versus mobile-bearing designs, offering contrasting trade-offs between implant stability and articulation kinematics.

Material selection emerges as a pivotal factor in performance differentiation. Ceramic-on-ceramic constructs provide exceptional wear resistance and biocompatibility, while metal-on-polymer configurations balance cost and mechanical robustness. Meanwhile, ceramic-on-polymer and metal-on-metal variants cater to specific clinical scenarios based on patient activity profiles and sensitivity considerations. These material permutations inform both R&D priorities and clinical adoption patterns.

Procedural segmentation bifurcates primary interventions-encompassing both partial and total joint replacements-from complex revision surgeries that address implant failure or anatomical irregularities. Primary total replacements command the bulk of procedure volumes, whereas targeted partial replacements are gaining traction for select patient cohorts. Finally, the care setting segmentation distinguishes ambulatory surgical centers from traditional hospital and clinic environments, reflecting a shift towards minimally invasive techniques and outpatient care pathways. By integrating these five segmentation axes, stakeholders can develop tailored value propositions, refine product portfolios, and optimize market penetration strategies across heterogeneous clinical landscapes.

Highlighting pivotal regional trends across the Americas Europe Middle East Africa and Asia-Pacific that inform strategic investment prioritization manufacturing footprint and market entry decisions

Within the Americas region, robust healthcare infrastructure and high per capita healthcare expenditure underpin a dynamic environment for joint replacement. North American markets exhibit mature payer models with an emphasis on value-based care, driving demand for implants that deliver demonstrable long-term outcomes. Latin American markets, while exhibiting growth potential, navigate resource constraints and variable reimbursement frameworks, necessitating flexible pricing models and targeted educational initiatives for surgeons and patients alike.

In Europe, Middle Eastern, and African territories, regulatory harmonization efforts have created a relatively standardized approval pathway for joint replacement devices, though reimbursement landscapes vary significantly. Western Europe prioritizes market access for next-generation biomaterials and digital surgery tools, whereas emerging markets in Eastern Europe, the Middle East, and Africa are characterized by gradual infrastructure development and selective adoption of premium implant technologies. Partnerships with local distributors and tailored training programs often facilitate market entry.

The Asia-Pacific region presents a heterogeneous tapestry of mature markets in Japan and Australia alongside rapidly evolving economies in China, India, and Southeast Asia. Rising life expectancy, increasing incidence of osteoarthritis, and expanding orthopaedic surgeon networks are catalyzing procedural volumes. Emphasis on cost containment and local manufacturing is prompting international players to establish regional facilities and collaborative R&D ventures, thereby unlocking new growth frontiers across this diverse region.

Examining the competitive landscape through in-depth analysis of leading hip and knee joint manufacturers product portfolios strategic collaborations and innovation roadmaps shaping industry leadership

Leading orthopaedic manufacturers have intensified their focus on innovation pipelines and strategic collaborations to consolidate market presence. Established players have expanded their portfolios through the acquisition of specialized technology firms, integrating sensor-enabled implants and smart instrumentations that provide intraoperative feedback. At the same time, emerging challengers are disrupting the status quo by innovating modular designs and exploring novel biomaterial composites with enhanced biomechanical compatibility.

Strategic alliances between original equipment manufacturers and software developers are accelerating the digital transformation of surgical workflows. These collaborations encompass preoperative planning platforms, intraoperative guidance systems, and postoperative analytics tools that collectively enhance clinical decision-making. Moreover, multinational corporations are leveraging joint ventures and local acquisitions to gain footholds in high-growth geographies, aligning production capacities with regional demand curves while navigating complex regulatory landscapes.

An increasing emphasis on comprehensive service offerings, including surgeon training programs, patient education portals, and value-based care contracts, underscores the shift towards integrated care models. Companies that provide bundled solutions-combining implant devices, instrumentation, and rehabilitation support-are positioning themselves as partners in patient outcome improvement rather than mere suppliers. This holistic approach is reshaping competitive dynamics and elevating the bar for operational excellence across the industry.

Delivering actionable recommendations for industry leaders to optimize growth through technology adoption supply chain diversification regulatory engagement and patient-centric service models

Industry leaders should prioritize the adoption of digital surgical platforms to harness data-driven insights that refine implant selection, optimize surgical precision, and monitor postoperative recovery trajectories. Implementing cloud-based analytics and artificial intelligence tools can translate procedure-level data into actionable recommendations, thereby improving both clinical outcomes and operational efficiencies.

Supply chain resilience must be bolstered through diversification of sourcing networks and strategic nearshoring initiatives. Engaging with domestic component manufacturers and exploring tariff relief mechanisms can mitigate geopolitical risks while preserving cost competitiveness. Concurrently, proactive dialogue with regulatory bodies is essential to streamline approval processes for next-generation implant technologies and to secure reimbursement pathways that reflect their long-term value proposition.

To capture emerging market potential, companies should tailor portfolio strategies to local clinical practices, pricing sensitivities, and surgeon preferences. Cultivating alliances with regional key opinion leaders and investing in localized training initiatives will facilitate market penetration. Additionally, embracing outcome-based contracting models and value-based care frameworks will underscore a commitment to patient-centricity and strengthen partnerships with payers and healthcare providers.

Outlining a robust research methodology integrating primary expert interviews secondary data analysis regulatory review and rigorous validation protocols to ensure actionable market intelligence

This research analysis was underpinned by a rigorous methodology that combined primary and secondary data sources. Primary research involved in-depth interviews with leading orthopaedic surgeons, hospital procurement managers, and industry experts to capture real-world insights into implant adoption, procedural trends, and emerging clinical needs. Secondary research encompassed a comprehensive review of regulatory filings, peer-reviewed journals, professional association publications, and medical device registries to contextualize these insights within broader industry frameworks.

Data triangulation was employed to reconcile divergent perspectives and ensure robustness of findings. Quantitative inputs from clinical registries and procedural databases were cross-referenced with qualitative interview responses to validate assumptions regarding technology uptake, segmentation dynamics, and competitive positioning. This multi-layered approach facilitated a holistic understanding of market forces while minimizing potential biases.

Rigorous validation protocols, including peer reviews and iterative expert consultations, were instituted throughout the research process. While efforts were made to encompass diverse geographies and stakeholder viewpoints, certain limitations-such as variable data availability across emerging markets and the evolving nature of tariff policies-were acknowledged and accounted for in the analysis. These methodological safeguards ensure that the resulting intelligence is both reliable and actionable for strategic decision-making.

Synthesizing key findings to conclude on market resilience innovation trajectories patient outcome imperatives and strategic imperatives for stakeholders in the artificial joint ecosystem

In synthesizing these insights, it becomes evident that the artificial hip and knee joint sector is at a pivotal juncture characterized by rapid technological evolution, shifting policy landscapes, and dynamic regional growth patterns. The convergence of robotic-assisted surgery, additive manufacturing, and advanced biomaterials is redefining implant performance and enabling more personalized treatment pathways.

Simultaneously, external factors such as the 2025 tariff adjustments underscore the importance of agile supply chain management and proactive policy engagement. By integrating multi-dimensional segmentation strategies, stakeholders can tailor their offerings to specific clinical scenarios, patient profiles, and care settings, thereby maximizing market relevance and competitive advantage.

Looking ahead, sustained emphasis on data-driven decision-making, patient-centric outcomes, and collaborative innovation will be instrumental in shaping the next phase of growth. Companies that effectively align technological capabilities with regulatory compliance and regional market realities will be best positioned to drive long-term value creation and improve the quality of life for patients worldwide.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

• 4.1. Introduction
• 4.2. Market Sizing & Forecasting

5. Market Dynamics

• 5.1. Rapid adoption of patient-specific 3D printed hip implants reducing surgical complications
• 5.2. Rising integration of AI algorithms in post-operative monitoring systems for knee arthroplasty patients
• 5.3. Shift towards cementless fixation techniques to improve osseointegration in knee joint replacements
• 5.4. Development of high-wear resilient polyethylene liners to extend artificial hip joint longevity
• 5.5. Increasing use of modular implant systems to allow intraoperative customization during hip surgeries
• 5.6. Emergence of smart sensor-enabled joint implants for real-time biomechanical performance feedback
• 5.7. Regulatory fast-track approvals for next-generation ceramic composite knee prostheses amid aging populations

6. Market Insights

• 6.1. Porter's Five Forces Analysis
• 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Artificial Hip & Knee Joints Market, by Joint Type

• 8.1. Introduction
• 8.2. Hip Joint
• 8.3. Knee Joint

9. Artificial Hip & Knee Joints Market, by Fixation Type

• 9.1. Introduction
• 9.2. Fixed-bearing Joint
• 9.3. Mobile-bearing Joint

10. Artificial Hip & Knee Joints Market, by Material Type

• 10.1. Introduction
• 10.2. Ceramic On Ceramic
• 10.3. Ceramic On Polymer
• 10.4. Metal On Metal
• 10.5. Metal On Polymer

11. Artificial Hip & Knee Joints Market, by Surgery Type

• 11.1. Introduction
• 11.2. Primary
  • 11.2.1. Partial Replacement
  • 11.2.2. Total Replacement
• 11.3. Revision

12. Artificial Hip & Knee Joints Market, by End User

• 12.1. Introduction
• 12.2. Ambulatory Surgical Centers
• 12.3. Hospitals & Clinics

13. Americas Artificial Hip & Knee Joints Market

• 13.1. Introduction
• 13.2. United States
• 13.3. Canada
• 13.4. Mexico
• 13.5. Brazil
• 13.6. Argentina

14. Europe, Middle East & Africa Artificial Hip & Knee Joints Market

• 14.1. Introduction
• 14.2. United Kingdom
• 14.3. Germany
• 14.4. France
• 14.5. Russia
• 14.6. Italy
• 14.7. Spain
• 14.8. United Arab Emirates
• 14.9. Saudi Arabia
• 14.10. South Africa
• 14.11. Denmark
• 14.12. Netherlands
• 14.13. Qatar
• 14.14. Finland
• 14.15. Sweden
• 14.16. Nigeria
• 14.17. Egypt
• 14.18. Turkey
• 14.19. Israel
• 14.20. Norway
• 14.21. Poland
• 14.22. Switzerland

15. Asia-Pacific Artificial Hip & Knee Joints Market

• 15.1. Introduction
• 15.2. China
• 15.3. India
• 15.4. Japan
• 15.5. Australia
• 15.6. South Korea
• 15.7. Indonesia
• 15.8. Thailand
• 15.9. Philippines
• 15.10. Malaysia
• 15.11. Singapore
• 15.12. Vietnam
• 15.13. Taiwan

16. Competitive Landscape

• 16.1. Market Share Analysis, 2024
• 16.2. FPNV Positioning Matrix, 2024
• 16.3. Competitive Analysis
  • 16.3.1. Smith & Nephew plc
  • 16.3.2. Zimmer Biomet Holdings, Inc.
  • 16.3.3. AMPLITUDE SAS
  • 16.3.4. B. Braun SE
  • 16.3.5. Corin Group Limited
  • 16.3.6. Enovis Corporation
  • 16.3.7. Exactech, Inc.
  • 16.3.8. Globus Medical, Inc.
  • 16.3.9. Implantcast GmbH
  • 16.3.10. Johnson & Johnson Services, Inc.
  • 16.3.11. KYOCERA Medical Technologies, Inc.
  • 16.3.12. Maxx Orthopedics, Inc.
  • 16.3.13. Medacta International SA
  • 16.3.14. Medtronic plc
  • 16.3.15. Merete GmbH
  • 16.3.16. MicroPort Scientific Corporation
  • 16.3.17. Narang Medical Limited
  • 16.3.18. Ossur hf.
  • 16.3.19. Otto Bock HealthCare LP
  • 16.3.20. restor3d, Inc.
  • 16.3.21. Signature Orthopaedics
  • 16.3.22. Stryker Corporation
  • 16.3.23. Surgival SL
  • 16.3.24. Tecomet, Inc.

17. ResearchAI

18. ResearchStatistics

19. ResearchContacts

20. ResearchArticles

21. Appendix